logo
Plus   Neg
Share
Email

Alnylam, Dicerna Form RNAi Therapeutics Collaboration For Alpha-1 Liver Disease

Alnylam Pharmaceuticals, Inc. (ALNY) and Dicerna Pharmaceuticals, Inc. (DRNA) said Monday they have formed a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin or A1AT deficiency-associated liver disease (alpha-1 liver disease).

In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam's lumasiran and Dicerna's nedosiran investigational programs to treat primary hyperoxaluria or PH.

The companies expect these agreements will enhance and accelerate their ability to bring these orphan product candidates to market.

Under the development and commercialization agreement, Alnylam's ALN-AAT02 and Dicerna's DCR-A1AT, two investigational RNAi therapeutics that are in Phase 1/2 development, will be explored for the treatment of alpha-1 liver disease.

Under the agreement, Dicerna will assume responsibility for both ALN-AAT02 and DCR-A1AT at its cost, and may progress one or both of these investigational medicines through clinical development.

Dicerna will select which product candidates to advance in development for the treatment of patients with alpha-1 liver disease. At Phase 3 completion, Alnylam has the no-cost opportunity to opt-in to commercialize the selected candidate in countries outside the U.S., where it already has a commercialization infrastructure in place.

If Alnylam exercises its opt-in right, each party shall pay tiered royalties to the other party based on net product sales generated in its territory at rates dependent on which candidate is commercialized.

If Alnylam waives its commercialization option, Dicerna will retain worldwide rights to commercialize the selected candidates in exchange for milestones and royalties payable to Alnylam. The rate will be dependent on which candidate is ultimately commercialized.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL.
Follow RTT